Navigation Links
Kendle Names Jarrod Pontius Chief Legal Officer
Date:6/29/2009

CINCINNATI, June 29 /PRNewswire-FirstCall/ -- Kendle (Nasdaq: KNDL), a leading, global full-service clinical research organization, today announced the appointment of Jarrod Pontius to the position of Chief Legal Officer. In this role, Pontius will provide global leadership for all legal services, corporate governance and general corporate legal matters for Kendle. Pontius will be based in Kendle's global headquarters in Cincinnati and will report to Chairman and Chief Executive Officer, Candace Kendle, PharmD. He will serve on the Company's Executive Committee.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080923/CLTU095LOGO )

"I am pleased to welcome Jarrod back to Kendle," said Dr. Kendle. "He brings a broad base of legal expertise as well as Kendle experience and we are happy to have a professional of his caliber to lead our global legal team. Jarrod has been instrumental in a number of our recent acquisitions and will be key to the future growth of Kendle."

Pontius brings more than a decade of experience in both the legal and corporate legal environments to Kendle. He has a demonstrated track record of success in the areas of corporate law, mergers and acquisitions, corporate development, public company reporting and securities compliance, corporate financing activities and corporate governance. He rejoins Kendle, from General Cable Corporation, a Fortune 500 publicly traded supplier of wire and cable products, where he had served as Assistant General Counsel since 2007. Previously Pontius was Corporate Counsel and Senior Corporate Counsel from 2002 through 2007 for Kendle. His experience also includes serving as an Associate in the business/corporate department of the Cincinnati law firm Frost Brown Todd LLC.

Pontius is a member of both the Cincinnati and Ohio Bar Associations and the Association of Corporate Counsel and is a graduate of the Cincinnati Academy of Leadership for Lawyers. He received his Juris Doctorate from Case Western Reserve University in Cleveland and holds a Bachelor of Science in finance from Indiana University.

About Kendle

Kendle International Inc. (Nasdaq: KNDL) is a leading global clinical research organization providing the full range of early- to late-stage clinical development services for the world's biopharmaceutical industry. Our focus is on innovative solutions that reduce cycle times for our customers and accelerate the delivery of life-enhancing drugs to market for the benefit of patients worldwide. As one of the fastest-growing global providers of Phase I-IV services, we offer experience spanning more than 100 countries, along with industry-leading patient access and retention capabilities and broad therapeutic expertise, to meet our customers' clinical development challenges.

Additional information and investor kits are available upon request from Kendle, 441 Vine Street, Suite 500, Cincinnati, OH 45202 or from the Company's Web site at www.kendle.com.


'/>"/>
SOURCE Kendle International Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Kendle Expands Asia/Pacific Operations with Opening of Offices in Kuala Lumpur, Bangkok and Manila
2. Kendle Announces First Quarter 2009 Results
3. Kendle Announces Departure of Senior Vice President and CFO Karl Buzz Brenkert III; Appoints Keith A. Cheesman as Successor
4. Kendle to Host Conference Call to Discuss Revised 2009 Outlook
5. Kendle Senior Scientist Edward Sellers, MD, PhD, Named One of Nine Notable People in R&D
6. Kendle to Present at Upcoming Barclays Capital and Raymond James Conferences
7. Kendle Announces Details Regarding Fourth Quarter and Full-Year 2008 Earnings and 2009 Guidance Release, Webcast and Conference Call
8. Kendle to Present at the 2008 Raymond James Boston Fall Investors Conference
9. Kendle to Present at the 2008 Credit Suisse Health Care Conference
10. Kendle Reappoints Former CFO Timothy M. Mooney to Board of Directors
11. Kendle Named a Best Place to Work in Greater Cincinnati
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... Bay, Florida (PRWEB) , ... October 11, 2017 ... ... and Drug Administration (FDA) has granted orphan drug designation to SBT-100, its novel ... (sdAb) for the treatment of osteosarcoma. SBT-100 is able to cross the cell ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... company advancing targeted antibody-drug conjugate (ADC) therapeutics, today confirmed licensing rights that ... Polymerized Liposomal Nanoparticle), a technology developed in collaboration with Children’s Hospital Los ...
(Date:10/10/2017)... Poway, California (PRWEB) , ... October 10, 2017 , ... ... afternoon speaking at his local San Diego Rotary Club. The event ... San Diego, CA and had 300+ attendees. Dr. Harman, DVM, MPVM was joined ...
(Date:10/10/2017)... Calif. , Oct. 10, 2017 SomaGenics ... from the NIH to develop RealSeq®-SC (Single Cell), expected ... for profiling small RNAs (including microRNAs) from single cells ... Program highlights the need to accelerate development of approaches ... "New techniques for measuring levels ...
Breaking Biology Technology:
(Date:4/13/2017)... April 13, 2017 According to a new market ... Identity Analytics, Identity Administration, and Authorization), Service, Authentication Type, Deployment Mode, Vertical, ... Market is expected to grow from USD 14.30 Billion in 2017 to ... of 17.3%. ... MarketsandMarkets Logo ...
(Date:4/11/2017)... 2017 No two people are believed ... New York University Tandon School of Engineering and ... that partial similarities between prints are common enough ... phones and other electronic devices can be more ... lies in the fact that fingerprint-based authentication systems ...
(Date:4/5/2017)... SEATTLE , April 5, 2017  The Allen ... the Allen Cell Explorer: a one-of-a-kind portal and dynamic ... large-scale 3D imaging data, the first application of deep ... edited human stem cell lines and a growing suite ... the platform for these and future publicly available resources ...
Breaking Biology News(10 mins):